Navigation Links
Jazz Pharmaceuticals Completes $7 Million Private Placement
Date:7/7/2009

PALO ALTO, Calif., July 7, 2009 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc. (Nasdaq: JAZZ) today announced the signing and closing of a private placement of an aggregate of 1,895,734 units, comprised of an aggregate of 1,895,734 shares of common stock and warrants to purchase up to 947,867 additional shares of common stock for aggregate gross proceeds of approximately $7 million. The per unit purchase price for a share of common stock and a warrant to purchase 0.50 of a share of common stock was $3.6925. The warrants have an exercise price of $4.00 per share and are exercisable for seven years.

The gross proceeds of the private placement were $7.0 million, and the company intends to use the proceeds for general corporate purposes. The units were purchased by funds affiliated with Longitude Capital. In connection with the transaction, Patrick Enright, a Managing Director of Longitude Capital, joined Jazz Pharmaceuticals' Board of Directors.

The securities offered and sold by Jazz Pharmaceuticals in this private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or state securities laws and may not be offered or sold in the United States absent registration with the Securities and Exchange Commission ("SEC") or an applicable exemption from registration requirements. Jazz Pharmaceuticals has agreed to file a registration statement with the SEC covering resale of the shares of common stock and the shares of common stock issuable upon exercise of the warrants issued in the private placement.

About Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals is a specialty pharmaceutical company that identifies, develops and commercializes innovative treatments for important, underserved markets in neurology and psychiatry. For further information plea
'/>"/>

SOURCE Jazz Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/3/2015)... Birth Boot Camp , a ... have over 130 certified instructors in more than 30 ... addition, the company recently launched a new doula ... certification program . Birth Boot Camp is unique because ... The practical information can be used by the couple ...
(Date:3/3/2015)... PLAINSBORO, N.J. (PRWEB) March 03, 2015 ... Simon Cancer Center have joined forces to share ... OncLive announced today. The collaboration is part of ... the new alliance, OncLive’s editorial and marketing teams ... a National Cancer Institute-designated cancer center, to highlight ...
(Date:3/3/2015)... Charleston, SC (PRWEB) March 03, 2015 March ... Collins for the 200th episode. The episode was a unique ... the fourth season, but because it featured two men who ... a car accident. At the beginning of the episode, Deierlein ... several times on my radio show, but I’m very excited ...
(Date:3/3/2015)... Celestix Networks, the leading provider ... the global availability of Celestix Cloud Edge Security ... most deployed platform for DirectAccess and remote access ... new release enables organizations to manage the Windows® ... single HTML 5 web interface called Comet 2.0. ...
(Date:3/3/2015)... Presale tickets for Madonna will be ready for purchase ... March 9, with Madonna tour tickets expected to sell out ... talented artist is a significant one for fans, and the ... Ticketability.com to browse the inventory of Madonna tickets at ... enjoy, the 2015 tour is expected to attract attention from ...
Breaking Medicine News(10 mins):Health News:Expectant Couples Worldwide Can Now Receive Training and Education in Natural Childbirth and Breastfeeding from Birth Boot Camp 2Health News:IU Simon Cancer Center Teams with OncLive® in Strategic Alliance Partnership 2Health News:IU Simon Cancer Center Teams with OncLive® in Strategic Alliance Partnership 3Health News:My Positive Perspective Releases Episode #200 With Car Accident and Coma Survivor Nick Collins 2Health News:Introducing Celestix Cloud Edge Security 2.0 for Increased Security in DirectAccess Client Management 2Health News:Introducing Celestix Cloud Edge Security 2.0 for Increased Security in DirectAccess Client Management 3Health News:Presale Tickets for Madonna: Ticketability.com Announces Madonna Tour Tickets for Sale at Reduced Prices for the Rebel Heart Tour During Presales 2
... beat has a basic rhythm in which it beats. The ... is a sustained heart rhythm abnormality,// medical advice is immediately ... to time, in other words a missed heart beat, or ... a lack of co-ordination of the electrical activity which keeps ...
... out of Switzerland finds children who are exposed to greater ... asthma or allergies. Researchers had parents of children ages 7 ... They also took blood samples from the kids to test ... from the children's bedding to test for levels of endotoxin, ...
... procurable in the doctor's office or the drugstore to test ... of the Government Chemist) have been working to produce a ... and produces results within 15 to 20 minutes. ... shoebox for ease of use in doctors' offices or drugstores. ...
... the treatment naltrexone is effective among those with a ... distinguish two patterns of drinking// - the Anglo-Saxon/Scandinavian pattern, ... the weekend and holidays, and the Mediterranean pattern, where ... The Anglo-Saxon pattern has been linked most often with ...
... for cancer has mostly been very beneficial to patients.Around six ... have a clear genetic cause. And we now know// at ... them. Dr.Lindsay Prior, a sociologist at Cardiff University felt that ... be advised to have the test. The reasons are technical, ...
... to a new study a clot-buster injection may unclog ... Rothenburger, M.D., researcher from University Hospital in Germany,// ... very serious problem for heart failure patients who receive ... device is a mechanical pump-like device that is surgically ...
Cached Medicine News:
(Date:3/3/2015)... , March 3, 2015  Delcath Systems, Inc. ... and medical device company focused on oncology with ... metastatic liver cancers, announces that the results from ... in 2009, have been submitted for publication in ... utilized Melphalan Hydrochloride for Injection for use with ...
(Date:3/3/2015)... DUBLIN , Mar. 03, 2015 Research ... announced the addition of SNS Research,s new report ... - Opportunities, Challenges, Strategies & Forecasts" to ... drug is a pharmaceutical product, usually intended to ... manufactured without a license from the innovator company ...
(Date:3/3/2015)... 2015 Mapi incorporates the expertise ... the drug development and commercialization process. ... Regulatory services with the addition of the CanReg Group, ... . CanReg is one of North America,s ... affairs for life sciences companies. With nearly 100 consultants, ...
Breaking Medicine Technology:Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 2Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 3Delcath Announces Submission Of Phase 3 Trial Results For Publication In A Leading Peer-Reviewed Medical Journal 4Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 2Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 3Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 4Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 5Generic Drugs a $350 Billion Opportunity According to 'The Generic Drugs Market: 2015-2030 - Opportunities, Challenges, Strategies & Forecasts' 6Mapi incorporates Strategic Regulatory Services to support life-science product Commercialization and Health Research 2
... TT™ offers the ultimate research level wireless ... knowledgeable clinician and researcher today. Offering superb ... to meet your desired footprint requirements. Choose ... display live data both in the room ...
... expectations with state of the art software ... to meet the needs of your busy ... be upgraded to grow with you. With ... management, it is easy to see why ...
... offers ultimate flexibility by allowing you to ... and display. Wall-mount anywhere in the room. ... a laptop, touch screen tablet, industrial PC, ... this multi-function patient tower provides more power ...
... Advanced diagnostic capabilities combined with ease ... best product in its class. Ideal for ... a complete system for Uroflowmetry, cystometry, leak ... (8) configurations are available which make the ...
Medicine Products: